Anti-CD19 antibodies with reduced immunogenicity

Patent metadata

Field	Value
Publication number	US-11208496-B2
Application number	US-201816126296-A
Country	US
Kind code	B2
Filing date	Sep 10, 2018
Priority date	Dec 30, 2005
Publication date	Dec 28, 2021
Grant date	Dec 28, 2021

Abstract

Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.

First claim

What is claimed is:

1. A pharmaceutical composition comprising:
i) in a pharmacologically effective amount an anti-CD19 antibody or polypeptide comprising:

(a) a heavy chain variable region that is at least 95% identical to SEQ ID NO: 13; and
(b) a light chain variable region that is at least 95% identical to SEQ ID NO: 25;
and
ii) a pharmaceutically acceptable diluent, carrier, or excipient.

Assignees

• Cancer Research Tech Ltd

Inventors

• Super Michael
• Davis Jonathan
• Stein Pascal Andre

Classifications

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P21/04

  for myasthenia gravis · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title